Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

8.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.1K
Lineage Commitment01:21

Lineage Commitment

3.4K
Commitment is the  process whereby stem cells:
3.4K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

9.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
9.8K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

1.5K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype.

Blood neoplasia·2026
Same author

Age-associated hematopoietic variants in the rhesus macaque.

Blood advances·2026
Same author

Disparate leukemia mutations converge on nuclear phase-separated condensates.

Cell·2025
Same author

Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia.

Experimental hematology·2025
Same author

Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres.

RMD open·2025
Same author

Author Correction: Clonal dynamics and somatic evolution of haematopoiesis in mouse.

Nature·2025

Related Experiment Video

Updated: May 3, 2026

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
11:00

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Published on: December 16, 2016

6.7K

Hematopoietic stem cell development: an epigenetic journey.

Sean M Cullen1, Allison Mayle2, Lara Rossi3

  • 1Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas, USA; Program in Developmental Biology, Baylor College of Medicine, Houston, Texas, USA.

Current Topics in Developmental Biology
|January 21, 2014
PubMed
Summary
This summary is machine-generated.

Epigenetic marks are crucial for hematopoietic stem cells (HSCs) self-renewal and development. Aberrant epigenetic changes are linked to hematological malignancies, highlighting their role in both normal and malignant hematopoiesis.

Keywords:
DNA methylationDevelopmentDnmt3aEpigenetic regulationHSCHematopoiesisHematopoietic stem cellsHistone modificationLeukemia

More Related Videos

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors
11:42

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors

Published on: November 4, 2019

7.5K
Epigenetic Regulation of Cardiac Differentiation of Embryonic Stem Cells and Tissues
13:03

Epigenetic Regulation of Cardiac Differentiation of Embryonic Stem Cells and Tissues

Published on: June 3, 2016

7.9K

Related Experiment Videos

Last Updated: May 3, 2026

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
11:00

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Published on: December 16, 2016

6.7K
Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors
11:42

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors

Published on: November 4, 2019

7.5K
Epigenetic Regulation of Cardiac Differentiation of Embryonic Stem Cells and Tissues
13:03

Epigenetic Regulation of Cardiac Differentiation of Embryonic Stem Cells and Tissues

Published on: June 3, 2016

7.9K

Area of Science:

  • Hematology
  • Epigenetics
  • Stem Cell Biology

Background:

  • Hematopoietic stem cells (HSCs) are essential for blood development and homeostasis, possessing self-renewal and multilineage potential.
  • HSC regulation involves extrinsic factors (niche, signaling pathways) and intrinsic factors.
  • Emerging evidence highlights the critical role of epigenetic modifications in HSC development and function.

Purpose of the Study:

  • To review recent findings on the epigenetic regulation of normal and malignant hematopoiesis.
  • To elucidate the role of epigenetic marks in HSC emergence, self-renewal, lineage commitment, and aging.
  • To explore the connection between aberrant epigenetic marks and hematological malignancies.

Main Methods:

  • Literature review of studies on HSCs, epigenetics, and hematological cancers.
  • Analysis of research on chromatin accessibility and its impact on HSC developmental cascades.
  • Synthesis of findings linking epigenetic regulators to leukemogenesis.

Main Results:

  • Epigenetic marks, by controlling chromatin accessibility, directly influence HSC developmental processes.
  • Aberrant epigenetic marks are frequently observed in hematological malignancies.
  • Mutations in epigenetic regulators are implicated in the promotion of leukemogenesis.

Conclusions:

  • Epigenetics plays a fundamental role in the life of HSCs, from embryonic development to aging.
  • Understanding the epigenetic landscape of HSCs is crucial for diagnosing and treating hematological malignancies.
  • Targeting epigenetic mechanisms offers potential therapeutic strategies for blood cancers.